首页 > 市场调查报告书 > 製药

放射性皮肤炎市场规模、份额及成长分析（按产品、通路及地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1904281

放射性皮肤炎市场规模、份额及成长分析（按产品、通路及地区划分）－2026-2033年产业预测

Radiodermatitis Market Size, Share, and Growth Analysis, By Product (Topical, Oral Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球放射性皮肤炎治疗市场规模预计在 2024 年达到 4.7091 亿美元，从 2025 年的 4.9022 亿美元增长到 2033 年的 6.7607 亿美元，在预测期（2026-2033 年）内复合年增长率为 4.1%。

市场分析显示，放射性皮肤炎治疗产品的需求迫切。这种疾病严重影响接受放射治疗的绝大多数（高达95%）癌症患者，其中乳癌患者的发生率更高。初期，因新冠疫情期间医疗资源优先保障需求，导致放射治疗次数减少，市场一度受到衝击。然而，随着医疗机构调整策略并优先考虑安全的癌症治疗，市场成长机会正在涌现。此外，糖尿病和肥胖症的日益普及也加剧了癌症发生率的上升，相当一部分患者面临更高的放射性皮肤损伤风险。这些合併症患者风险的增加，也支撑了放射性皮肤炎治疗市场在不久的将来强劲的成长潜力。

全球放射性皮肤炎市场驱动因素

癌症治疗中放射线治疗的日益普及是放射性皮肤炎发生率上升的主要原因之一。随着越来越多的患者接受放射治疗，放射性皮肤炎的发生率预计也将相应增加。癌症治疗的趋势也因此推动了对有效放射性皮肤炎管理方案的需求。医疗机构和製药公司正被鼓励致力于开发创新治疗方法和产品，以满足因放射暴露而出现皮肤併发症的患者的特殊需求。治疗技术的进步与患者照护之间的相互作用，为放射性皮肤炎市场带来了充满活力的格局。

限制全球放射性皮肤炎市场的因素

全球放射性皮肤炎市场面临许多挑战，其中之一是某些治疗方案可能的副作用和不良反应。这些併发症可能会限制某些治疗方法在特定患者群体中的适用性，从而阻碍治疗方法的普及和疗效。医疗专业人员在权衡治疗方案的益处和潜在风险时，这些不良反应的存在可能会使患者对某些治疗方案望而却步，最终导致市场成长放缓。因此，透过研发更安全的替代疗法来解决这些问题，对于扩大市场规模和改善受影响患者的治疗可近性至关重要。

全球放射性皮肤炎治疗市场趋势

全球放射性皮肤炎市场正呈现出显着的趋势，即越来越多地采用先进治疗方法。这一趋势的特点是创新治疗方法的使用日益增多，包括专用外用产品和先进敷料，这些疗法因其在治疗放射性皮肤损伤方面的显着疗效而备受青睐。医疗服务提供者和患者越来越认识到标靶治疗不仅能缓解症状，还能促进皮肤癒合和恢復。因此，对这些最先进治疗的需求持续增长，反映出人们在改善放射性皮肤炎患者生活品质和治疗效果方面所做的努力。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

3M Company（United States）
Smith & Nephew plc（United Kingdom）
Investor AB（Molnlycke Health Care AB）（Sweden）
BMG Pharma SpA（Italy）
Stratpharma Inc.（Switzerland）
Bausch Health Companies Inc.（Canada）
Bayer AG（Germany）
Paul Hartmann AG（Germany）
KeraNetics, Inc.（United States）
Charles River Laboratories（United States）
The Jackson Laboratory（United States）
InterMed SA（Greece）
AceTech（South Korea）
KCI Licensing Inc.（Acelity）（United States）
Derma Sciences Inc.（Integra LifeSciences）（United States）
Ligand Pharmaceuticals Inc.（Apeiron Biologics）（United States）
Lutris Pharma Ltd.（Israel）
GlaxoSmithKline plc（United Kingdom）
ConvaTec Group plc（United Kingdom）
Viatris Inc（United States）

结论与建议

简介目录

Product Code: SQMIG35G2240

Global Radiodermatitis Market size was valued at USD 470.91 Million in 2024 and is poised to grow from USD 490.22 Million in 2025 to USD 676.07 Million by 2033, growing at a CAGR of 4.1% during the forecast period (2026-2033).

Market insights indicate a pressing demand for radiodermatitis treatment products, as this condition significantly impacts a vast majority of cancer patients undergoing radiation therapy-up to 95%, with breast cancer patients experiencing even higher rates. The market faced initial disruptions due to prioritization of COVID-19 healthcare needs, resulting in diminished radiation sessions. However, as healthcare institutions adapt and prioritize safe cancer treatments, growth opportunities are emerging. Additionally, the rising prevalence of diabetes and obesity contributes to an increasing incidence of cancer, with a notable portion of patients facing higher risks of radiation-induced skin damage. This heightened risk among co-morbid individuals underscores a robust potential for growth within the radiodermatitis treatment market in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiodermatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiodermatitis Market Segments Analysis

Global Radiodermatitis Market is segmented by Product, Distribution Channel and region. Based on Product, the market is segmented into Topical, Oral Drugs and Dressings. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Radiodermatitis Market

The growing utilization of radiation therapy in cancer treatment is a significant factor driving the rise in radiodermatitis incidents. As more patients undergo radiation as part of their care regimen, the prevalence of radiodermatitis cases is expected to climb correspondingly. This upward trend in cancer treatment approaches subsequently fuels the demand for effective radiodermatitis management solutions. Healthcare providers and pharmaceutical companies are thus prompted to focus on developing innovative therapies and products to address the unique needs of patients experiencing skin complications from radiation exposure. This synergy between treatment advancements and patient care illustrates the dynamic landscape of the radiodermatitis market.

Restraints in the Global Radiodermatitis Market

The Global Radiodermatitis market faces challenges due to the potential side effects and adverse reactions associated with certain treatment options. These complications can restrict the applicability of various therapies within specific patient demographics, thereby hindering their overall adoption and effectiveness. As healthcare professionals navigate the balance between treatment benefits and possible risks, the presence of these adverse effects could deter patients from pursuing certain therapies, ultimately leading to slower market growth. Addressing these concerns through research and development of safer alternatives may be essential to expanding the market and improving treatment accessibility for affected individuals.

Market Trends of the Global Radiodermatitis Market

The Global Radiodermatitis market is experiencing a notable trend towards the increasing adoption of advanced treatment options. This shift is marked by a rise in the use of innovative therapies, including specialized topical products and advanced dressings, which are becoming favored for their proven efficacy in managing radiation-induced skin damage. Healthcare providers and patients increasingly recognize the importance of targeted therapies that not only alleviate symptoms but also promote skin healing and recovery. As a result, the demand for these state-of-the-art treatments continues to expand, reflecting a broader commitment to enhancing patient quality of life and improving therapeutic outcomes in radiodermatitis management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Technology Assessment
Patent Analysis
Pipeline Analysis

Global Radiodermatitis Market Size by Product & CAGR (2026-2033)

Market Overview
Topical
- Corticosteroids
- Hydrophilic Creams
- Antibiotics
- Others
Oral Drugs
Dressings
- Hydrogel & Hydrocolloid dressings
- No Sting Barrier Film
- Honey-impregnated Gauze
- Silicone Coated Dressings
- Others

Global Radiodermatitis Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Radiodermatitis Market Size & CAGR (2026-2033)

North America (Product, Distribution Channel)
- US
- Canada
Europe (Product, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

3M Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith & Nephew plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Investor AB (Molnlycke Health Care AB) (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BMG Pharma S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stratpharma Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Paul Hartmann AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KeraNetics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
The Jackson Laboratory (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InterMed S.A. (Greece)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AceTech (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KCI Licensing Inc. (Acelity) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Derma Sciences Inc. (Integra LifeSciences) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals Inc. (Apeiron Biologics) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lutris Pharma Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ConvaTec Group plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments